Tirzepatide is superior to insulin glargine for management of type 2 diabetes and elevated cardiovascular risk
1. From baseline to 52 weeks, tirzepatide resulted in a greater reduction in mean HbA1c levels compared to insulin glargine. ...
Tag: glucose-dependent insulinotropic peptide (GIP)
Once weekly tirzepatide is superior to daily insulin degludec for treatment of uncontrolled type 2 diabetes
1. Patients receiving tirzepatide (5, 10, or 15 mg) reported significantly greater reductions in HbA1c compared to daily insulin degludec ...
Tirzepatide improves glycemic control and weight loss in patients with type 2 diabetes
1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of ...